

IN THE CLAIMS

This listing of the claims will replace all prior versions, and listings of claims in the application:

Listing of Claims

1-26. (Canceled)

27. (Currently amended) An isolated and purified alpha-1-acid glycoprotein (AAG) AAG substantially free of LPS, said AAG having a lipopolysaccharide (LPS) LPS concentration of less than or equal to 0.1 Eu/mg AAG.

28. (Currently amended) The AAG as claimed in of claim 27 wherein the AAG has a LPS level of less than 0.075 Eu/mg AAG.

29. (Currently amended) The AAG as claimed in of claim 27 wherein the AAG has a LPS level of less than 0.050 Eu/mg AAG.

30. (Currently amended) A virus inactivated or a virus depleted preparation of the AAG as claimed in of claim 27.

31. (Canceled)

32. (Currently amended) A method of treating AAG as defined in claim 27 for use in treatment of drug toxicity in a patient in need of such treatment comprising administering to the patient an effective amount of alpha-1-acid glycoprotein (AAG), wherein the AAG comprises less than or equal to 0.1 Eu lipopolysaccharide per mg AAG.

33. (Cancelled)

34. (Currently amended) A pharmaceutical composition comprising the AAG of as defined in claim 27 ~~together with one or more~~ and a pharmaceutically acceptable carriers carrier, or ~~excipients~~ excipient, diluent, or combination thereof.

35. (New) The pharmaceutical composition of claim 34, wherein the AAG comprises less than 0.075 Eu LPS/mg AAG.

36. (New) The pharmaceutical composition of claim 35, wherein the AAG comprises less than 0.050 Eu LPS/mg AAG.

37. (New) The pharmaceutical composition of claim 36, wherein the AAG comprises less than 0.02 Eu LPS/mg AAG.

38. (New) A pharmaceutical composition comprising an isolated and purified depyrogenated alpha-1-acid glycoprotein (AAG) comprising less than or equal to 0.1 Eu. lipopolysaccharide (LPS)/mg AAG and a pharmaceutically acceptable carrier, excipient, diluent or combination thereof.

39. (New) The method of claim 32, wherein the dose of AAG administered is about 10 g to about 30 g.

40. (New) The method of claim 32, wherein the toxicity is caused by a drug overdose.

41. (New) The method of claim 40, wherein the drug comprises a tricyclic anti-depressant.

42. (New) The method of claim 41, wherein the tricyclic antidepressant is amitriptyline, desipramine, or nortriptyline.

43. (New) The method of claim 40, wherein the drug comprises a basic drug.

44. (New) The method of claim 43, wherein the basic drug is quinine, lignocaine or propranolol.

45. (New) The method of claim 32, wherein the AAG is administered enterally, parenterally, by transmucosal delivery, by an implant, intravenously, intramuscularly or subcutaneously.